TY - JOUR
T1 - Requirement for innate immunity and CD90 NK1.1 lymphocytes to treat established melanoma with chemo-immunotherapy
AU - Moskalenko, Marina
AU - Pan, Michael
AU - Fu, Yichun
AU - De Moll, Ellen H.
AU - Hashimoto, Daigo
AU - Mortha, Arthur
AU - Leboeuf, Marylene
AU - Jayaraman, Padmini
AU - Bernardo, Sebastian
AU - Sikora, Andrew G.
AU - Wolchok, Jedd
AU - Bhardwaj, Nina
AU - Merad, Miriam
AU - Saenger, Yvonne
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2015/3
Y1 - 2015/3
N2 - We sought to define cellular immune mechanisms of synergy between tumor-antigen-targeted monoclonal antibodies and chemotherapy. Established B16 melanoma in mice was treated with cytotoxic doses of cyclophosphamide in combination with an antibody targeting tyrosinase-related protein 1 (aTRP1), a native melanoma differentiation antigen. We find that Fc g receptors are required for efficacy, showing that antitumor activity of combination therapy is immune mediated. Rag1-/- mice deficient in adaptive immunity are able to clear tumors, and thus innate immunity is sufficient for efficacy. Furthermore, previously treated wild-type mice are not significantly protected against tumor reinduction, as compared with mice inoculated with irradiated B16 alone, consistent with a primarily innate immune mechanism of action of chemoimmunotherapy. In contrast, mice deficient in both classical natural killer (NK) lymphocytes and nonclassical innate lymphocytes (ILC) due to deletion of the IL2 receptor common gamma chain IL2γc-/-) are refractory to chemo-immunotherapy. Classical NK lymphocytes are not critical for treatment, as depletion of NK1.1+ cells does not impair antitumor effect. Depletion of CD90+NK1.1- lymphocytes, however, both diminishes therapeutic benefit and decreases accumulation of macrophages within the tumor. Tumor clearance during combination chemo-immunotherapy with monoclonal antibodies against native antigen is mediated by the innate immune system. We highlight a novel potential role for CD90+NK1.1-ILCs in chemo-immunotherapy.
AB - We sought to define cellular immune mechanisms of synergy between tumor-antigen-targeted monoclonal antibodies and chemotherapy. Established B16 melanoma in mice was treated with cytotoxic doses of cyclophosphamide in combination with an antibody targeting tyrosinase-related protein 1 (aTRP1), a native melanoma differentiation antigen. We find that Fc g receptors are required for efficacy, showing that antitumor activity of combination therapy is immune mediated. Rag1-/- mice deficient in adaptive immunity are able to clear tumors, and thus innate immunity is sufficient for efficacy. Furthermore, previously treated wild-type mice are not significantly protected against tumor reinduction, as compared with mice inoculated with irradiated B16 alone, consistent with a primarily innate immune mechanism of action of chemoimmunotherapy. In contrast, mice deficient in both classical natural killer (NK) lymphocytes and nonclassical innate lymphocytes (ILC) due to deletion of the IL2 receptor common gamma chain IL2γc-/-) are refractory to chemo-immunotherapy. Classical NK lymphocytes are not critical for treatment, as depletion of NK1.1+ cells does not impair antitumor effect. Depletion of CD90+NK1.1- lymphocytes, however, both diminishes therapeutic benefit and decreases accumulation of macrophages within the tumor. Tumor clearance during combination chemo-immunotherapy with monoclonal antibodies against native antigen is mediated by the innate immune system. We highlight a novel potential role for CD90+NK1.1-ILCs in chemo-immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84962308492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962308492&partnerID=8YFLogxK
U2 - 10.1158/2326-6066.CIR-14-0120
DO - 10.1158/2326-6066.CIR-14-0120
M3 - Article
C2 - 25600438
AN - SCOPUS:84962308492
SN - 2326-6066
VL - 3
SP - 296
EP - 304
JO - Cancer Immunology Research
JF - Cancer Immunology Research
IS - 3
ER -